---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034848"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:20:47.804846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose

## Summary
- Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.
- Phase 1b PH-762 trial: 100% tumor clearance (complete response) in one patient at max dose, >90% in second, >50% in third.
- Cumulative pathologic results in 16 cSCC patients: 6 complete, 2 near complete, 2 partial responses; no dose-limiting toxicities.
- November 2025 warrant inducement financing expected to raise ~$12.1M, extending cash runway into first half 2027.
- Cash and equivalents $10.7M at Sep 30, 2025; estimated $21.3M as of release date.

## SEC filing metadata
- accession: 0001437749-25-034848
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774925034848/0001437749-25-034848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774925034848/phio20251001_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034848
- JSON: https://secwatch.observer/filing/0001437749-25-034848.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.